MrgB8 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of MrgB8, a member of the Mas-related G-protein-coupled receptor (MRGPR) family. MrgB8 is expressed predominantly in sensory neurons, where it is thought to play a critical role in modulating nociceptive signals, or the sensory perception of potentially harmful stimuli such as pain. As a G-protein-coupled receptor (GPCR), MrgB8 mediates cellular responses to external stimuli by binding to specific ligands, which in turn activate intracellular signaling pathways that regulate neuronal excitability and sensitivity. This receptor is particularly involved in processing signals related to mechanical, thermal, or chemical stimuli, making it a key player in the modulation of pain pathways. Inhibition of MrgB8 disrupts these sensory processes, providing researchers with a valuable tool to study its specific role in neuronal signaling and pain perception.
In research, MrgB8 inhibitors are valuable for exploring the molecular mechanisms underlying sensory neuron activation and the modulation of pain signals. By blocking MrgB8 activity, scientists can investigate how inhibition affects the way sensory neurons respond to harmful stimuli, focusing on how disruptions in this receptor's function influence nociceptive pathways and the overall processing of pain. This inhibition allows researchers to study downstream effects on intracellular signaling cascades, receptor-ligand interactions, and broader networks that regulate sensory perception. Additionally, MrgB8 inhibitors can be used to explore the interaction between MrgB8 and other GPCRs within the nociceptive system, shedding light on the complex regulatory circuits involved in controlling pain sensitivity and sensory neuron behavior. Through these studies, the use of MrgB8 inhibitors enhances our understanding of the role of GPCR signaling in sensory physiology and provides insights into the intricate mechanisms that govern the perception of pain and other external stimuli.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Pertussis Toxin (islet-activating protein) | 70323-44-3 | sc-200837 | 50 µg | $451.00 | 3 | |
An exotoxin that irreversibly inhibits G protein-coupled receptor signaling by ADP-ribosylation of the alpha subunit of the inhibitory G protein (Gi), which can affect MrgB8 activity. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
A polysulfonated naphthylurea that can non-selectively inhibit G protein-coupled receptor signaling by preventing receptor-G protein interactions. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor antagonist that can alter signaling in related GPCRs by competitive inhibition. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
A potent antagonist of Gs alpha subunit of G-proteins which can hinder GPCR-mediated signaling. | ||||||
YM 254890 | 568580-02-9 | sc-507356 | 1 mg | $510.00 | ||
A cyclic depsipeptide that selectively inhibits Gq proteins, and may indirectly influence MrgB8 activity by modulating GPCR signaling pathways. | ||||||
Scriptaid | 287383-59-9 | sc-202807 sc-202807A | 1 mg 5 mg | $64.00 $183.00 | 11 | |
An inhibitor of Gq/11 alpha proteins that can suppress downstream signaling of related GPCRs. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
A selective inhibitor of the Cdc42 GTPase, which interacts with G-protein signaling pathways and could modulate MrgB8 activity. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
A protein kinase C inhibitor that can disrupt GPCR-mediated signal transduction, possibly influencing MrgB8 function. | ||||||
Gallein | 2103-64-2 | sc-202631 | 50 mg | $85.00 | 20 | |
A small molecule that blocks G-beta-gamma signaling, which is downstream of GPCR activation and could impact MrgB8. | ||||||